Metastatic castration‐resistant prostate cancer patients with SPOP somatic mutations have higher response rates and treatment durations to the novel endocrine therapy abiraterone25; In our study, SPOP was remarkly higher in HR−/HER2+ subtype compared to that in HR+/HER2− and TNBC subtypes, and PTK2 and FAT4 were obviously higher in TNBC subtype than in the other three subtypes. The gene discussed is FAT4; the disease is prostate carcinoma.